8.07 USD
↘ 0.03 (0.37%)AT CLOSE (11:59 AM EDT)
ImmunityBio, Inc. Common Stock
IBRXNASDAQ • USD
8.00
↘ 0.08 (0.93%)
POST MARKET (AS OF 08:00 PM EDT)
Post Market
AS OF 08:00 PM EDT
8.00
↘ 0.08 (0.93%)
Market: CLOSED
Open?$8.27
High?$8.38
Low?$7.75
Prev. Close?$8.10
Volume?11.4M
Avg. Volume?21.8M
VWAP?$8.01
Rel. Volume?0.52x
Bid / Ask
Bid?$7.99 × 9.6K
Ask?$8.00 × 1.7K
Spread?$0.01
Midpoint?$8.00
Valuation & Ratios
Market Cap?8.4B
Shares Out?1.0B
Float?368.2M
Float %?35.8%
P/E Ratio?N/A
P/B Ratio?-16.71
EPS?-$0.34
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?5.10Strong
Quick Ratio?5.08Strong
Cash Ratio?1.43Strong
Debt/Equity?-0.65Low
ValuationFAIRLY VALUED
Score67/100
P/E?N/A▾
P/B?-16.71CHEAP▾
P/S?73.84HIGH▾
P/FCF?N/A▾
EV/EBITDA?-35.8CHEAP▾
EV/Sales?75.92HIGH▾
Returns & Efficiency
ROE?70.2%STRONG▾
ROA?-70.0%WEAK▾
Cash Flow & Enterprise
FCF?$-308782000
Enterprise Value?$8.6B
News
Profile
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Employees
691
Market Cap
8.4B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2021-03-10
Address
3530 JOHN HOPKINS COURT
SAN DIEGO, CA 92121
Phone: (844) 696-5235
SAN DIEGO, CA 92121
Phone: (844) 696-5235